Scarica l'app Stockscreener
13.85
0.24%
0.055
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Biopharma reaches patent settlement with Cipla on YUPELRI inhalation - Investing.com
Does Theravance Biopharma Inc. qualify in momentum factor screeningJuly 2025 Rallies & Verified Entry Point Detection - Newser
Using data models to predict Theravance Biopharma Inc. stock movementJuly 2025 Technicals & Smart Allocation Stock Tips - Newser
Theravance Biopharma Inc.’s volatility index tracking explainedWeekly Market Outlook & High Accuracy Buy Signal Tips - Newser
What’s the recovery path for long term holders of Theravance Biopharma Inc.2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
Best data tools to analyze Theravance Biopharma Inc. stock2025 Volatility Report & Proven Capital Preservation Tips - Newser
Is Theravance Biopharma Inc. a momentum stock2025 Winners & Losers & Daily Technical Stock Forecast Reports - classian.co.kr
What earnings revisions data tells us about Theravance Biopharma Inc.2025 Volatility Report & AI Powered Buy/Sell Recommendations - Newser
Using Ichimoku Cloud for Theravance Biopharma Inc. technicals2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Theravance Biopharma Inc. stock undervalued right now2025 Market WrapUp & Low Risk Entry Point Tips - classian.co.kr
Tools to monitor Theravance Biopharma Inc. recovery probabilityJuly 2025 Action & Daily Profit Focused Stock Screening - Newser
How Theravance Biopharma Inc. stock performs during market volatilityJuly 2025 Setups & High Accuracy Investment Signals - Newser
Is Theravance Biopharma Inc. still worth holding after the dip2025 Investor Takeaways & High Accuracy Swing Entry Alerts - Newser
Candlestick Signal Suggests Reversal in Theravance Biopharma Inc.2025 Volume Leaders & Real-Time Volume Analysis Alerts - metal.it
Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen - Defense World
What institutional flow reveals about Theravance Biopharma Inc.Weekly Investment Summary & Consistent Income Trade Ideas - Newser
Real time social sentiment graph for Theravance Biopharma Inc.2025 Top Decliners & AI Driven Price Predictions - Newser
Candlestick Reversal Detected on Theravance Biopharma Inc.’s ChartJuly 2025 Fed Impact & Reliable Volume Spike Alerts - metal.it
What makes Theravance Biopharma Inc. stock price move sharplyJuly 2025 Snapshot & Short-Term Trading Opportunity Alerts - thegnnews.com
H.C. Wainwright Maintains Buy Rating for Theravance Biopharma with $15 Price Target - AInvest
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
H.C. Wainwright Sticks to Their Buy Rating for Theravance Biopharma (TBPH) - The Globe and Mail
The 11% Return This Week Takes Theravance Biopharma's (NASDAQ:TBPH) Shareholders One-year Gains to 51% - 富途牛牛
Theravance Biopharma Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by XTX Topco Ltd - Defense World
Theravance Biopharma’s Earnings Call Highlights Strategic Gains - TipRanks
Theravance Biopharma, Inc. SEC 10-Q Report - TradingView
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates - NewsBreak: Local News & Alerts
Theravance Biopharma stock price target raised to $13 by Leerink Partners - Investing.com South Africa
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma stock price target raised to $13 by Leerink Partners By Investing.com - Investing.com Nigeria
Theravance Biopharma shares fall 1.85% premarket despite strong Q2 earnings and positive operational updates. - AInvest
Theravance Biopharma Q2 2025 Earnings Call Transcript - MarketBeat
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ... - Yahoo Finance
Theravance Sales Jump 83 Percent - AOL.com
Theravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High Following Strong Earnings - Defense World
Theravance anticipates $150M in milestones as CYPRESS trial nears pivotal data readout - MSN
Technical signs of recovery in Theravance Biopharma Inc. [Analyst Upgrade]Free Safe Entry Momentum Stock Tips - Newser
Theravance Biopharma Reports Strong Q2 2025 Results - TipRanks
Theravance Biopharma: Hold Rating Amid Temporary Revenue Gains and Pipeline Uncertainty - TipRanks
Theravance Biopharma Reports Q2 2025 Results with 83.2% Revenue Growth, Exceeding Analyst Expectations - AInvest
Theravance Bio: Q2 Earnings Snapshot - Big Rapids Pioneer
Theravance Sales Jump 83 Percent - The Motley Fool
Theravance Biopharma (TBPH): A High-Conviction Play on Rare Disease Innovation and Durable Cash Flow - AInvest
Contradictions Unveiled: Theravance Biopharma's 2025Q2 Earnings Call Highlights Pricing, Strategy, and Market Dynamics - AInvest
Theravance Biopharma Expects $150M in Milestone Payments as CYPRESS Trial Approaches Pivotal Data Readout - AInvest
Theravance Biopharma's Q2 Surge: A Case Study in Biotech Resilience and Strategic Precision - AInvest
Earnings call transcript: Theravance Biopharma Q2 2025 earnings beat expectations - Investing.com
Theravance Biopharma Q2 2025 slides: Revenue jumps 22%, cash position triples - Investing.com Canada
Theravance Biopharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Theravance Biopharma shares rise 1.51% after-hours after reporting strong Q2 2025 results. - AInvest
THERAVANCE BIOPHARMA Earnings Results: $TBPH Reports Quarterly Earnings - Quiver Quantitative
Theravance Biopharma earnings beat by $0.41, revenue topped estimates - Investing.com Canada
Theravance Biopharma shares fall 8.56% after-hours despite strong Q2 2025 earnings report. - AInvest
Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Placera.se
Theravance Biopharma reaffirms FY25 R&D expenses view $32M-$38M - TipRanks
Technical signs of recovery in Theravance Biopharma Inc.Daily Profit Watch With Forecast Confidence - Newser
0.58%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):